BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announced the submission of a Fentanyl Lauriad clinical trial application to the French Drug Agency (AFSSaPS) and its approval by the Ethics Committee (Comité de Protection des Personnes).

This phase-I clinical trial will recruit its first subjects before end 2009. Patented until 2030, Fentanyl Lauriad is based on the same muco-adhesive technology already validated with Loramyc, BioAlliance already marketed drug. This sustained release new product is dedicated to the treatment of cancer chronic pain.

Furthermore, BioAlliance Pharma's shareholders were invited to attend the Extraordinary and Ordinary General Assembly Meeting on July 27, 2009 to vote on a new governance structure with a Board of Directors and corresponding changes of the by-laws. A total of a 7,238,991 shares, representing 56.20 per cent of existing shareholders, were attending or were represented at the Meeting. The resolution received 66.06 per cent of the votes. As 66.67 per cent were necessary to allow the structural changes, the current organisation of the Supervisory Board and Management Board will be maintained.

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a specialty biopharmaceutical company which develops and markets innovative products, especially in the fields of opportunistic infections and chemotherapy complications.